Our study shows that plasma Lp(a) levels are elevated not only in CAD patients (very high risk patients), but also in those without CAD who are at high risk to develop CAD, highlighting that therapy and preventable measures should be used at this stage to reduce risk of atherosclerosis development. Here, LPA is linked to coronary artery disorder.